Immunovia

”The name PancreaSure embodies the benefit of our test: providing accurate pancreatic cancer detection to give medical professionals and patients clarity and reassurance when they need it most,” said Jeff Borcherding, CEO of Immunovia.

PancreaSure has demonstrated strong clinical performance across multiple studies, achieving 78% sensitivity and 92% specificity in identifying early-stage pancreatic cancer. This performance meets or exceeds that of the most common screening methods used today. In contrast to current common methods, which are more invasive and burdensome for patients, PancreaSure is a simple blood test.

“Compared to our prior test, PancreaSure represents a very different test run on a different testing platform. That warranted a new name to mark significant advancement for pancreatic cancer screening for high-risk individuals. With PancreaSure, we want to transform early detection when survival chances are dramatically higher,” Borcherding said.

PancreaSure is set to launch commercially in the United States in the third quarter of 2025, initially targeting approximately 200 specialized centers that run high-risk pancreatic cancer surveillance programs.